Dietary Supplements

Fearing links to human health problems and harm to the environment, state lawmakers are increasingly seeking to restrict the use and/or presence of PFAS in consumer products and packaging, whether intentionally added or not.

As more and more consumers turn to dietary supplements to fill nutrition gaps and support general health and wellness, a growing number of state governments are seeking to regulate these products to ensure the health and safety of constituents who may be consuming them. One area of interest to policymakers in recent years is the category of weight loss products.

OTC medical devices like bandages, menstrual products, face masks, and at-home test kits, used for the purposes of prevention, testing, and treatment are well-accepted, cost saving elements of the healthcare system. Unfortunately, most states that have a retail sales tax, include a tax on the sale of some or all OTC healthcare products. More than 40 states, on the other hand, exempt sales tax of prescription drugs.

CHPA released the below statement following the passage of A1848 by the New Jersey Assembly today. This legislation seeks to ban the sale of over-the-counter (OTC) weight loss diet pills and dietary supplements marketed for weight loss and muscle building to individuals under 18 years old. While CHPA accepts age restrictions on products explicitly marketed for weight loss, recent amendments to the bill have broadened its scope. The changes now unnecessarily encompass general health supplements containing certain ingredients – including creatine and green tea extract – which are commonly used in many products unrelated to weight loss.

(WASHINGTON, DC) – The Health In Hand Foundation today released the following statement announcing the 2024 U.S. Self-Care Marketing Awards finalists. Winners for each category will be announced at the 9th annual Health In Hand Foundation Gala on November 13 at The Bellevue Hotel in Philadelphia. Specific awards will recognize the strategic innovation and marketing expertise of CHPA member companies across over-the-counter (OTC) medicine, consumer medical device, and dietary supplement categories.

CHPA Senior Vice President of Dietary Supplements Duffy MacKay released the following statement today in response to a recent JAMA Network Open Study investigating the prevalence and characteristics of U.S. adults consuming botanicals potentially linked to liver toxicity:

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) today released the following statement after providing input to U.S. House Energy & Commerce Committee Members, U.S. Representatives Larry Bucshon (IN-08) and Diana DeGette (CO-01), following their request for information from industry stakeholders on how Congress can build upon the 21st Century Cures Act and Cures 2.0 to develop and deliver a new generation of treatments: